Senores Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹36.60 Crore on Total Income of ₹201 Crore
Earnings
pharmaceuticals
Blacklitt Research3 min read
B.Lachner, via Wikimedia Commons (CC0). Illustrative image.
Senores Pharmaceuticals (NSE: SENORES) reported consolidated total income of ₹201.27 crore and net profit of ₹36.60 crore for the quarter ended 30 Sep 2026, it said in a filing on 29 Oct 2026. Standalone total income was ₹50.41 crore and standalone net profit ₹7.72 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹201.27 crore, up 20.4% YoY and 10.0% QoQ
Net profit and EPS: ₹36.60 crore, up 21.5% YoY; basic EPS ₹8.85
Finance costs: ₹8.77 crore, up 41.7% YoY and 22.3% QoQ
Standalone
The company on its own, without its subsidiaries
Total income: ₹50.41 crore, up 8.0% YoY and 38.0% QoQ
Net profit and EPS: ₹7.72 crore, up 20.1% YoY; basic EPS ₹1.68
Other income: ₹14.76 crore, down 21.0% YoY
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
201.27
167.17
+20.4%
183.02
+10.0%
Revenue from operations
192.33
153.94
+24.9%
180.21
+6.7%
Other income
8.94
13.23
-32.4%
2.81
+218.1%
36.60
30.12
+21.5%
30.45
+20.2%
Profit before tax
47.58
40.64
+17.1%
39.46
+20.6%
Finance costs
8.77
6.19
+41.7%
7.17
+22.3%
Depreciation
10.25
8.09
+26.7%
9.94
+3.1%
Tax expense
10.98
10.51
+4.5%
9.01
+21.9%
Net profit margin
18.18%
18.02%
+0.17 pp
16.64%
+1.55 pp
EPS, basic (₹)
8.85
6.54
+35.3%
6.61
+33.9%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income.
Other income of ₹8.94 crore is 4.4% of consolidated total income and 18.8% of profit before tax of ₹47.58 crore. Finance costs of ₹8.77 crore are 4.4% of total income, rising 41.7% from ₹6.19 crore a year earlier, faster than revenue.
Tax expense of ₹10.98 crore is 23.1% of profit before tax this quarter, compared with ₹10.51 crore a year earlier on a lower profit before tax of ₹40.64 crore. The filing gives no reason for the change in tax charge; the auditors' review carries an emphasis of matter that tax provisions and deferred tax have been determined as estimated by management solely.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
50.41
46.69
+8.0%
36.54
+38.0%
Revenue from operations
35.65
28.01
+27.3%
26.99
+32.1%
Other income
14.76
18.68
-21.0%
9.55
+54.6%
7.72
6.43
+20.1%
1.03
+649.5%
Profit before tax
9.67
7.65
+26.4%
1.39
+595.7%
Finance costs
2.22
1.58
+40.5%
2.22
0.0%
Depreciation
3.93
3.65
+7.7%
3.61
+8.9%
Tax expense
1.95
1.23
+58.5%
0.36
+441.7%
Net profit margin
15.31%
13.77%
+1.54 pp
2.82%
+12.50 pp
EPS, basic (₹)
1.68
1.40
+20.0%
0.22
+663.6%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 20.1% YoY to ₹7.72 crore, while standalone total income rose 8.0%. Revenue from operations rose 27.3% to ₹35.65 crore and other income fell 21.0% to ₹14.76 crore. Other income is 29.3% of standalone total income and 152.6% of standalone profit before tax of ₹9.67 crore.
Standalone profit before tax rose 26.4% to ₹9.67 crore, and tax expense rose 58.5% to ₹1.95 crore, about 20.2% of profit before tax. Standalone finance costs of ₹2.22 crore are 4.4% of total income, up 40.5% YoY.
Against the previous quarter, standalone net profit rose 649.5% from ₹1.03 crore and profit before tax rose from ₹1.39 crore, while total income rose 38.0%. The filing gives no reason for the standalone other income or tax movements.
Consolidated net profit of ₹36.60 crore is ₹28.88 crore higher than standalone net profit of ₹7.72 crore. Consolidated total income of ₹201.27 crore is ₹150.86 crore higher than standalone total income of ₹50.41 crore. The consolidated results include Apnar Pharma Private Limited, acquired 75% on 16 Jan 2026, along with the Senores Pharmaceuticals Inc, Havix Group Inc, Ratnatris Pharmaceuticals Private Limited subsidiaries and three step-down subsidiaries.
The media release says the company is on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27, and that initial set-up and operating costs of Zoraya and Amerisyn, without corresponding revenue, held back EBITDA. Consolidated EBITDA was ₹58 crore, up 38% YoY.
Inference
The filing states that the board approved the joint statutory auditors Talati and Talati LLP for 2026-27 to 2030-31, subject to shareholders' approval, and that IPO proceeds of ₹418.83 crore of ₹500 crore had been utilised by 30 Sep 2026, leaving ₹81.17 crore unutilised. The 11,70,000 warrants allotted on 28 Mar 2026 at ₹812 each carry a ₹95 crore aggregate, of which ₹23.75 crore had been received; the filing does not say whether the warrants have been converted or the balance paid.
The filing does not give the reason for the lower standalone other income or the change in standalone tax rate, and does not give the timing of the balance 25% Apnar stake acquisition.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
SENORESSenores Pharmaceuticals Ltd.